Krystal Biotech (NASDAQ:KRYS) Announces Earnings Results

Krystal Biotech (NASDAQ:KRYS - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18), Zacks reports. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million.

Krystal Biotech Stock Up 1.0 %

NASDAQ KRYS traded up $1.35 on Friday, hitting $138.52. The company's stock had a trading volume of 42,606 shares, compared to its average volume of 296,601. The company's 50-day moving average is $172.42 and its 200 day moving average is $170.36. The firm has a market cap of $4.00 billion, a PE ratio of 46.33 and a beta of 0.79. Krystal Biotech has a 1-year low of $132.48 and a 1-year high of $219.34.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

KRYS has been the topic of several research reports. Chardan Capital reaffirmed a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday. Citigroup upped their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Guggenheim cut their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, Jefferies Financial Group started coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech currently has an average rating of "Buy" and a consensus price target of $218.63.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).